Literature DB >> 9128932

Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.

J M Friedman1, P H Birch.   

Abstract

Type 1 Neurofibromatosis, NF1, is a common genetic disorder with variable clinical manifestations. Although NF1 often is only of cosmetic concern, serious and even lethal complications may occur. It is not possible to predict which symptoms will develop in any affected individual. The NNFF International Database is a multicentre collaborative system for collecting information about this condition. At the time of this analysis, complete clinical information was available on 1,479 probands and 249 of their affected relatives with NF1. On average, the age at diagnosis of NF1 was 8 years younger in the probands than in the affected relatives (P<.01). Many of the manifestations of NF1 were more frequent in the probands than in their affected relatives. The age-specific prevalence of most manifestations of NF1 increases with age. Despite biases inherent in a convenience sample from specialist clinics, the frequencies of many of the serious manifestations of NF1 are similar to those of two smaller population-based studies. The frequencies in this study are likely representative of patients seen at specialized clinics.

Entities:  

Mesh:

Year:  1997        PMID: 9128932     DOI: 10.1002/(sici)1096-8628(19970516)70:2<138::aid-ajmg7>3.0.co;2-u

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  102 in total

Review 1.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  Von recklinghausens disease: a series of four cases with variable expression.

Authors:  K P Arun; P Thomas Joseph; H P Jaishankar; M S Abhinethra
Journal:  J Maxillofac Oral Surg       Date:  2013-02-07

4.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

Authors:  Weixi Wang; Jeffry S Nyman; Koichiro Ono; David A Stevenson; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2011-07-14       Impact factor: 6.150

5.  Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Authors:  Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; David Janhofer; Eva Dombi; Richard S Dunn; Mi-Ok Kim; Andrea R Masters; David R Jones; Timothy P Cripe; Nancy Ratner
Journal:  Pediatr Blood Cancer       Date:  2015-04-22       Impact factor: 3.167

Review 6.  Neural phenotypes of common and rare genetic variants.

Authors:  Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson
Journal:  Biol Psychol       Date:  2008-02-23       Impact factor: 3.251

7.  Neurofibromatosis of the nipple-areolar area: a case series.

Authors:  Maria Rita Bongiorno; Spyridoula Doukaki; Mario Aricò
Journal:  J Med Case Rep       Date:  2010-01-25

8.  Cerebral vasculopathy in a Chinese family with neurofibromatosis type I mutation.

Authors:  Jian-Tao Liang; Li-Rong Huo; Yu-Hai Bao; Zhen-Yu Wang; Feng Ling
Journal:  Neurosci Bull       Date:  2013-11-11       Impact factor: 5.203

9.  Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome.

Authors:  Michel De Vos; Bruce E Hayward; Susan Picton; Eamonn Sheridan; David T Bonthron
Journal:  Am J Hum Genet       Date:  2004-04-07       Impact factor: 11.025

10.  NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F.

Authors:  Simona Parrinello; Luke A Noon; Marie C Harrisingh; Patrick Wingfield Digby; Laura H Rosenberg; Catherine A Cremona; Pedro Echave; Adrienne M Flanagan; Luis F Parada; Alison C Lloyd
Journal:  Genes Dev       Date:  2008-12-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.